iNtRON Biotechnology Inc (048530) — Capital Reinvestment Ratio
Latest as of March 2025:
0.17x
iNtRON Biotechnology Inc (048530) has a Capital Reinvestment Ratio of 0.17x as of March 2025, meaning it reinvests 0% of its operating cash flow (₩1.94 Billion) in capital expenditures (₩321.62 Million). See 048530 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.17x
Capex / Operating Cash Flow
Operating Cash Flow
₩1.94 Billion
KRW
Capital Expenditures
₩321.62 Million
KRW
Data as of
Mar 2025
Most recent filing
iNtRON Biotechnology Inc Capital Reinvestment Ratio (2015–2023)
This chart tracks iNtRON Biotechnology Inc's Capital Reinvestment Ratio across 6 annual periods.
Annual Capital Reinvestment Ratio for iNtRON Biotechnology Inc (2015–2023)
Year-by-year Capital Reinvestment Ratio for iNtRON Biotechnology Inc from 2015 to 2023. For live market cap and broader valuation context, see how much is iNtRON Biotechnology Inc worth.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 3.06x | ₩3.12 Billion | ₩9.55 Billion | ▲ +721.6% |
| 2022 | 0.37x | ₩5.98 Billion | ₩2.23 Billion | ▲ +101.6% |
| 2021 | 0.18x | ₩16.47 Billion | ₩3.05 Billion | ▼ -72.8% |
| 2020 | 0.68x | ₩7.13 Billion | ₩4.85 Billion | ▲ +419.1% |
| 2018 | 0.13x | ₩4.20 Billion | ₩550.58 Million | ▼ -96.5% |
| 2015 | 3.71x | ₩1.70 Billion | ₩6.30 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow